CPL Biologicals aims to be a leading provider of high quality, affordable vaccines, biologics and diagnostics through world-class research and innovations combined with cost effective and efficient manufacturing to address current and future global health challenges.
Virus Like Particle is similar to a virus in structure but without the genetic material required for viral replication. Once VLPs are injected into the body, they trigger a potent immune response.
Read More
Genetic sequences encoding vaccine antigens are selected and cloned into baculovirus. The baculovirus infects insect (Sf9) cells to express Antigens. The antigens are purified as multimeric nanoparticles.
Read More
CPL Biologicals utilizes biological systems, living organisms or derivatives thereof, to develop and commercialize products for novel, affordable solutions for global healthcare.
Virus Like Particles (VLP) and Recombinant Nanoparticle Technology gives us significant advantage over conventional vaccines for speed of development, safety and efficacy.
CPL Biologicals has established
state-of-the-art cGMP manufacturing facilities in compliance with global quality and regulatory expectations.
